Exclusive Summary

• **Potential Best-in-Class Biobetter**: Leverages the validated CTLA-4-Fc fusion protein mechanism but engineered for superior affinity and potency, aiming to outperform BMS's Orencia® (Abatacept).
• **Superior Preclinical Profile**: Demonstrates 30-fold higher binding affinity to CD80 and 262-fold to CD86, with over 100-fold greater in vitro biological activity compared to Abatacept, plus pH-dependent binding properties.
• **Clinically Validated Safety**: Phase I data indicates excellent safety and tolerability with no Serious Adverse Events (SAEs) or withdrawals due to AEs; absence of ADCC/CDC effects further minimizes safety risks.
• **Strategic Indication Expansion**: Beyond the massive Rheumatoid Arthritis (RA) market, specifically targets Graft-versus-Host Disease (GVHD) and Immune-Related Adverse Events (irAEs), addressing critical unmet needs in immuno-oncology supportive care.

Asset Materials

Contact Us for Full Materials